In appendiceal cancers, the most frequently mutated genes are (i) KRAS, which, when reactivated, restores signal transduction via the RAS–RAF–MEK–ERK signaling pathway and stimulates cell proliferation in the early stages of tumor transformation, and then angiogenesis; (ii) TP53, whose inactivation leads to the inhibition of programmed cell death; (iii) GNAS, which, when reactivated, links the cAMP pathway to the RAS–RAF–MEK–ERK signaling pathway, stimulating cell proliferation and angiogenesis; (iv) SMAD4, exhibiting typical tumor-suppressive activity, blocking the transmission of oncogenic TGFB signals via the SMAD2/SMAD3 heterodimer; and (v) BRAF, which is part of the RAS–RAF–MEK–ERK signaling pathway. Diverse mutations are reported in other genes, which are part of secondary or less critical signaling pathways for tumor progression, but which amplify the phenotypic diversity of appendiceal cancers. In this review, we will present the main genetic mutations involved in appendix tumors and their roles in cell proliferation and survival, and in tumor invasiveness, angiogenesis, and acquired resistance to anti-growth signals.

Antibiotic resistance represents a growing public health threat, with airborne drug-resistant strains being especially alarming due to their ease of transmission and association with severe respiratory infections. The respiratory microbiome plays a pivotal role in maintaining respiratory health, influencing the dynamics of antibiotic resistance among airborne pathogenic microorganisms. In this context, this review proposes the exploration of the complex interplay between the respiratory microbiota and antimicrobial resistance, highlighting the implications of microbiome diversity in health and disease. Moreover, strategies to mitigate antibiotic resistance, including stewardship programs, alternatives to traditional antibiotics, probiotics, microbiota restoration techniques, and nanotechnology-based therapeutic interventions, are critically presented, setting an updated framework of current management options. Therefore, through a better understanding of respiratory microbiome roles in antibiotic resistance, alongside emerging therapeutic strategies, this paper aims to shed light on how the global health challenges posed by multi-drug-resistant pathogens can be addressed.

Background/Objectives: Maintenance hemodialysis patients are particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to evaluate clinical outcomes and identify admission laboratory biomarkers associated with in-hospital mortality in hospitalized hemodialysis patients with coronavirus disease 2019 (COVID-19). Methods: We conducted a retrospective observational study including 130 adult hemodialysis patients with confirmed SARS-CoV-2 infection. Clinical characteristics and admission laboratory parameters were analyzed in relation to in-hospital outcomes using comparative, multivariable logistic regression, and receiver operating characteristic (ROC) curve analyses. Results: The overall in-hospital mortality rate was 34.6%. The median age of the cohort was 66 years, with 64.6% male patients. Non-survivors showed significantly higher levels of inflammatory and tissue-injury markers, including C-reactive protein (CRP) (p < 0.001) and lactate dehydrogenase (LDH) (p < 0.001), together with lower serum albumin (p < 0.001), platelet count (p < 0.001), and lymphocyte levels (p = 0.03). In multivariable analysis, cardiovascular disease, respiratory disease, dyspnea, and ambulatory origin were independently associated with mortality. ROC analysis identified platelet count as the best individual predictor (area under the curve [AUC] = 0.767). An exploratory composite risk score demonstrated excellent discriminative performance (AUC = 0.902). Conclusions: Admission inflammatory and hematological biomarkers are strongly associated with adverse outcomes in hospitalized hemodialysis patients with COVID-19. The integration of clinical and laboratory parameters into a composite risk score may improve early risk stratification and support clinical decision-making in this high-risk population.

Patients receiving maintenance hemodialysis were highly vulnerable during the coronavirus disease 2019 pandemic because treatment continuity required repeated exposure to healthcare settings, while multiple comorbidities increased severe infection risk. Although many studies reported clinical outcomes in dialysis populations, fewer assessed hospitalization costs, particularly in Eastern Europe. This study evaluated hospitalization costs among maintenance hemodialysis patients admitted with COVID-19 during pandemic waves in Romania: Wave 1 (March–May 2020), Wave 2 (October 2020–February 2021), and Wave 3 (July–November 2021). We conducted a retrospective cohort study using linked administrative and clinical databases from a Romanian tertiary nephrology center. The source database included 126 entries. After exclusion of records lacking complete reimbursement or admission/discharge data, 84 hospitalization episodes were eligible for analysis. The dataset included the first two waves: 23 admissions in Wave 1 and 61 in Wave 2. Mean hospitalization cost increased from 6,216.51 RON in Wave 1 to 8,478.76 RON in Wave 2, while median cost increased from 3,094.44 RON to 5,281.90 RON. Mean length of stay decreased significantly from 18.39 to 11.61 days (P = 0.0047). Mean cost per hospitalization day increased significantly from 426.30 RON/day to 767.47 RON/day (P = 0.0013). Total hospitalization cost correlated positively with length of stay (Spearman’s ρ = 0.50, P < 0.001). Data from Wave 3 were limited and interpreted descriptively. The second pandemic wave was associated with shorter admissions and higher daily hospitalization costs, suggesting more intensive inpatient management. These findings support prioritization of dialysis patients in future preparedness and healthcare resource planning.

Background/Objectives: Patients undergoing chronic hemodialysis are at increased risk of severe COVID-19 outcomes. This study aimed to evaluate the clinical characteristics and prognostic factors associated with mortality in hemodialysis patients infected with SARS-CoV-2. Methods: We conducted a retrospective study including 130 chronic hemodialysis patients diagnosed with COVID-19 and admitted to a nephrology unit between March 2020 and April 2021. Demographic data, comorbidities, clinical manifestations, hospitalization duration, and outcomes were analyzed using univariate and multivariate statistical methods. Results: The cohort was predominantly male (64.6%), with a mean age of 64.0 ± 13.9 years. The mean hospitalization duration was 13.6 ± 9.7 days. Cardiovascular disease, chronic respiratory disease, dyspnea at presentation, and hospital-origin admission were significantly associated with mortality. While diabetes mellitus and hypertension were highly prevalent, they did not independently predict mortality after adjustment. Overall mortality was 34.6%, particularly among older patients with multiple comorbidities. Conclusions: COVID-19 infection is associated with substantial morbidity and mortality among patients on chronic hemodialysis. Early identification of high-risk patients based on clinical presentation and comorbidity profile may support timely intervention and improved outcomes in this vulnerable population.